| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/23/2003 | EP1328546A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 07/23/2003 | EP1328545A1 Human gene critical to fertility |
| 07/23/2003 | EP1328527A1 Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents |
| 07/23/2003 | EP1328524A2 Novel anticholinergics, method for the production thereof and use thereof as medicaments |
| 07/23/2003 | EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof |
| 07/23/2003 | EP1328294A2 Combination use of acetylcholinesterase inhibitors and gaba-a inverse agonists for the treatment of cognitive disorders |
| 07/23/2003 | EP1328291A2 Viruses targeted to hypoxic cells and tissues |
| 07/23/2003 | EP1328289A2 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof |
| 07/23/2003 | EP1328288A2 Protein mixtures for wound healing |
| 07/23/2003 | EP1328287A1 Compositions and methods for wt1 specific immunotherapy |
| 07/23/2003 | EP1328277A1 Method for the preparation of a pharmaceutical composition, and its use |
| 07/23/2003 | EP1328276A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 07/23/2003 | EP1328271A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328270A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328269A2 Association of the cb1 receptor antagonist and a sibutramin for treating obesity |
| 07/23/2003 | EP1328268A1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 07/23/2003 | EP1328267A2 Method of treating cancer using dithiocarbamate derivatives |
| 07/23/2003 | EP1328266A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 07/23/2003 | EP1328265A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 07/23/2003 | EP1328261A2 Treatment of neurodegenerative disease |
| 07/23/2003 | EP1328253A2 Administration of a thiol-based chemoprotectant compound |
| 07/23/2003 | EP1254260A4 Methods for diagnosing and treating heart disease |
| 07/23/2003 | EP1154785B1 Inhibitors for use in hemostasis and immune function |
| 07/23/2003 | EP1107741B1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 07/23/2003 | EP1079818B1 Composition comprising il-18 and topotecan for treatment and/or prevention of cancer |
| 07/23/2003 | EP1053012B1 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections |
| 07/23/2003 | EP0961613A4 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis |
| 07/23/2003 | EP0930831B1 Flavonol containing food supplements |
| 07/23/2003 | EP0914166B1 Methods of terminal sterilization of biological products |
| 07/23/2003 | EP0888278B1 Antidiabetic agents |
| 07/23/2003 | EP0873137B1 Compositions including calcium influx blockers for inhibiting cell growth |
| 07/23/2003 | CN1432022A Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| 07/23/2003 | CN1431998A Growth hormone secretagogues |
| 07/23/2003 | CN1431915A Treatment of congestive heart failure with compsn. comprising diuretic agent and vasopressin antagonist |
| 07/23/2003 | CN1431912A Combination product comprising melagatran and factor Xa inhibitor |
| 07/23/2003 | CN1431909A Combinations for treating neoplasms |
| 07/23/2003 | CN1431907A Method of treating hepatitis delta viral infection |
| 07/23/2003 | CN1431902A Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 07/23/2003 | CN1431900A Methods and compsns. useful in enhancing oxygon delivery to cells |
| 07/23/2003 | CN1431298A Antineoplastic immunocompetent cell-cell of DCIC, its preparing method and applications |
| 07/23/2003 | CN1430970A Application of Nano copper powder for preparing medicine for prophylaxis of osteoporosis and bone fracture |
| 07/23/2003 | CN1115151C Mixture of vasodilating agents and medical diluet or carrier in prepn. of medicine for treating liver disease |
| 07/22/2003 | US6596867 Bone disorders |
| 07/22/2003 | US6596851 Antibody for use in the treatment of cell proliferative disorders |
| 07/22/2003 | US6596769 20-Hete antagonists and agonists |
| 07/22/2003 | US6596767 Adjustment of fat concentration |
| 07/22/2003 | US6596761 Cosmetic and dermatological preparation with flavonoids |
| 07/22/2003 | US6596754 Preventives/remedies for multiple organ failure |
| 07/22/2003 | US6596747 For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596733 Nitric oxide scavengers, such as dithiocarbamate-containing compounds, are used to reduce side effects caused by therapeutical administration of nitric oxide sources |
| 07/22/2003 | US6596729 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
| 07/22/2003 | US6596723 Fungal efflux pump inhibitors |
| 07/22/2003 | US6596720 Potentiating an anti-HIV activity of trifluridine and derivatives in thereof in a mammal, including human, comprising administering to said mammal, including human, an effective amount of a thymidine phosphorylase inhibitor and |
| 07/22/2003 | US6596703 Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids |
| 07/22/2003 | US6596701 S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| 07/22/2003 | US6596700 Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides |
| 07/22/2003 | US6596533 Polypeptide for use in the treatment of infections and cell proliferative disorders |
| 07/22/2003 | US6596491 Tenascin-C nucleic acid ligands |
| 07/22/2003 | US6596477 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A |
| 07/22/2003 | US6596474 Kit for use in the detection and treatment of nervous system disorders |
| 07/22/2003 | US6596401 Polyurethane-urea-silane copolymer along with active agent such as antibiotic for coating medical devices such as catheters or IUDs |
| 07/22/2003 | US6596320 Combination regimen of platinum agent, taxane agent and toxicity reducing agent such as cisplatin, paclitaxel and dimesna |
| 07/22/2003 | US6596298 Pullulan and antimicrobially effective amounts of thymol, methyl salicylate, eucalyptol and menthol |
| 07/22/2003 | US6596268 Viruses for the treatment of cellular proliferative disorders |
| 07/22/2003 | US6596206 Generation of pharmaceutical agent particles using focused acoustic energy |
| 07/22/2003 | CA2294422C Tartrate salt of a substituted dipeptide |
| 07/22/2003 | CA2228572C Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy |
| 07/21/2003 | CA2416791A1 A receptor-ligand pairing for immune response |
| 07/21/2003 | CA2368656A1 Receptor-ligand pairing for anti-inflammatory response |
| 07/17/2003 | WO2003057926A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | WO2003057919A2 The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
| 07/17/2003 | WO2003057911A2 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057730A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | WO2003057673A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | WO2003057669A1 Androgen receptor antagonists |
| 07/17/2003 | WO2003057666A2 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057650A2 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
| 07/17/2003 | WO2003057264A1 Feminine care products for the delivery of therapeutic substances |
| 07/17/2003 | WO2003057255A1 Drugs against obeisty and drugs against fatty liver |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057250A1 Cancer treatment |
| 07/17/2003 | WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | WO2003057235A2 Modification of feeding behavior |
| 07/17/2003 | WO2003057225A2 Phosphate transport inhibitors |
| 07/17/2003 | WO2003057222A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | WO2003057218A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | WO2003057217A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
| 07/17/2003 | WO2003057205A2 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 07/17/2003 | WO2003057202A1 Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
| 07/17/2003 | WO2003057201A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057178A2 Viral capsid assembly intermediates |
| 07/17/2003 | WO2003057172A2 Topical application of alpha-dfmo and anti-inflammatory drug for treatment of actinic keratoses |
| 07/17/2003 | WO2003057168A2 Cancer-associated epitope |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |